Novel Therapeutics in MS

Slides:

Advertisements

Similar presentations

UK clinical perspective on treatment reviews of multiple sclerosis therapies Alasdair Coles Neurologist, Cambridge, UK.

Advertisements

By Matthew Sampson. Overview What is it? Previous Treatments Monoclonal Antibodies Chimeric Molecules Oral Therapies Hematopoietic Stem Cells Future.

Emerging MS Therapies. Limitations of Current Therapies All are only partially effective All are injectable or IV and have side effects Risks vs benefits.

Multiple sclerosis: Oral Therapies and Beyond

Immune Depletion, Immune Modulation, and Immunosuppression in MS: A Review.

Systemic Lupus Erythematosus

IL-12 and IL-23.

Highlights From the 2015 European Multiple Sclerosis Meeting

Highlights From the 2017 Annual European MS Meeting

Introduction/Background

Perspectives on Key MS Data From the Annual European MS Meeting

MS Highlights From the 2017 Annual Neurology Meeting

Program Goals Teriflunomide: Pooled Safety Data.

Learning Goals. Harnessing the Immune System: Mechanism of Action of Immunotherapies in B-Cell Malignancies.

Discussion Outline Cells of the Immune System.

Immune Reconstitution in MS:

What Predicts Disability Progression in Multiple Sclerosis?

Current Controversies in Multiple Sclerosis Management

Applying Real-World Evidence in MS: Reviewing the State of the Art

Perspectives on Key MS Data From the Annual Neurology Meeting

What’s the Big Deal About Brain Atrophy and Neurodegeneration in RRMS?

T-Cell Directed Therapy in MS

Current and Future Goals in the Treatment of Relapsed CLL

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

Optimizing Patient Outcomes in IBD

Chronic Idiopathic Urticaria

Challenges in Managing Progressive Multiple Sclerosis

Assessing Disease Progression in MS Treatment

Clinical Updates in RA: New Developments and Insights From Washington

Oral vs IV High-Dose Methylprednisolone Are Equally Effective in MS

Novel Therapies for the Treatment of MS

Updates in Lymphoma From Recent Congresses

The Emerging Role of Immunotherapy in Hodgkin Lymphoma

Gene Therapy: Past, Present, and Future

Charting Progress in MS Treatment:

Immunotherapy for cSCC

Treating to Target in MS

The Evolving Treatment Landscape in Atopic Dermatitis

The three primary ADC components that determine which cells are targeted (antibody), how the drug is released (linker/trigger), and the mechanism of action.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Expert Perspectives on the Clinical Use of Immune Reconstitution vs Escalation Therapy for MS.

Program Goals Overview Is NEDA a Reasonable Target?

Expert Perspectives on New Data in Multiple Sclerosis From the 2018 European MS Meeting.

Opportunistic Infections in MS What Is the Risk?

Clinical Pearls on Hot Topics in MS

Non-Chemotherapy Combinations in CLL

Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.

NEDA 2-Year Endpoint: Not a Predictor of Long-Term Stability?

Emerging Multiple Sclerosis Therapies

Calliope A. Dendrou, Lars Fugger Neuron

Inhaled Antibiotics for Patients With CF in the Era of CFTR Modulators

Program Goals Overview Natalizumab Natalizumab: Recent Label Changes.

Secondary Progressive Multiple Sclerosis: What Do We Know and Where Are We Heading?

Program Goals Overview Is NEDA a Reasonable Target?

Oral Therapies in MS.

Optimizing Outcomes for Patients With Systemic Lupus Erythematosus: Key Considerations.

Treatment of Multiple Sclerosis: Old & New

Clinical Challenges in the Patient With Relapsed Multiple Myeloma

Targeting Apoptosis in AML

PAH Pathways: What Do the Data Tell Us?”

Mitigating Infection Risk With DMT in MS

The ABCs of Therapeutic Strategies in Pregnancy and Multiple Sclerosis

MS, Age, and Immune Function

Updates in Progressive MS

Targeting Glioblastoma: EGFR and Novel Approaches to Therapy

Understanding the Role of Disability in MS Management

Selective Immunomodulation in MS

Fresh perspectives ON BASAL Insulins in diabetes care

You Don't Know JAK in IBD.

Presentation transcript:

Novel Therapeutics in MS

Role of T Cells in MS

Role of B Cells in MS

Role of T Cells and B Cells in Disease Progression

T-Cell and B-Cell Targeted Therapies

T-Cell and B-Cell Targeted Therapies (cont)

Natalizumab: MOA

Natalizumab: Clinical Outcomes

Altering the Immune Function of T Cells and B Cells

Fingolimod: MOA

Fingolimod: Clinical Outcomes

Alemtuzumab: MOA

Alemtuzumab: Clinical Outcomes

Cladribine: MOA

Cladribine: Clinical Outcomes

Daclizumab: MOA

Daclizumab: Clinical Outcomes

Investigational T-Cell Targeting Therapies: Siponimod

S1PR Modulators

Investigational T-Cell Targeting Therapies: Other

B-Cell Ontogeny

Ocrelizumab: ORATORIO Study in PPMS

Immune-Depleting Strategies

Investigational B-Cell Targeted Therapies: Ofatumumab

Investigational B-Cell Targeted Therapies: Ofatumumab (cont)

Investigational B-Cell Targeted Therapies: Ublituximab and Inebilizumab

Looking to the Future

Conclusions

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)